Current Disease Therapy News and Events

Current Disease Therapy News and Events, Disease Therapy News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 25 | 1000 Results
Tuberculosis: New biomarker indicates individual treatment duration
The treatment of tuberculosis (TB) is long and demanding. In particular, in cases of resistant tuberculosis, the WHO generally recommends a standard treatment duration of at least 18 months, as there are no reliable biomarkers for an early termination. Under the leadership of the DZIF scientists at the Borstel Research Center have now succeeded in identifying a biomarker that points to an individual end of therapy based on the activity of 22 genes. In many cases, this probably allows the treatment to be shortened safely. (2021-02-19)

Physical therapy after c-section improves outcomes
Women who received physical therapy after undergoing a cesarean section had significantly improved outcomes compared to those who did not according to a new study from University of Missouri Health Care. (2021-02-17)

Friends fur life help build skills for life
A new UBC Okanagan study finds children not only reap the benefits of working with therapy dogs-they enjoy it too. (2021-02-17)

Penn-developed CAR T therapy shows long-lasting remissions in non-hodgkin lymphoma
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah™, researchers in Penn's Abramson Cancer Center reported today in the New England Journal of Medicine. (2021-02-17)

Psychotherapy for panic disorder shows positive long-term effects
Psychotherapy for panic disorder produces good results, and the effects are lasting. That is the result from a large long-term study from Lund University in Sweden. Two years after treatment were 70 per cent of the patients clearly improved and 45 per cent were remitted. (2021-02-16)

Moffitt uses mathematical modeling to identify factors that determine adaptive therapy success
In a new article featured on this month's cover of Cancer Research, Moffitt Cancer Center researchers, in collaboration with Oxford University, report results from their study using mathematical modeling to show that cell turnover impacts drug resistance and is an important factor that governs the success of adaptive therapy. (2021-02-15)

Researchers assess cognitive impairment in patients with breast cancer
A recent analysis of published studies in Psycho-Oncology estimates that one-quarter of adults with breast cancer have cognitive impairment before starting therapy. (2021-02-03)

Imaging identifies breast cancer patients unlikely to benefit from hormone therapy
Hormone therapy can be very effective for so-called estrogen receptor-positive breast cancer. But it only works for a little more than half of women who receive the treatment. In a small study, researchers at Washington University School of Medicine in St. Louis found that women whose tumors did not respond to a one-day estrogen challenge did not benefit from hormone therapy. The findings could help doctors choose treatments most likely to help their patients. (2021-02-02)

Moffitt researchers identify why CAR T therapy may fail in some lymphoma patients
In a new study published in Blood, the official journal of the American Society of Hematology, Moffitt researchers show that immune dysregulation can directly affect the efficacy of CAR T therapy in patients with diffuse large B-cell lymphoma. (2021-02-02)

Novel therapy-resistance mechanism promoting the growth of breast cancer brain metastasis
SORLA is a protein trafficking receptor that has been mainly studied in neurons, but it also plays a role in cancer cells. Professor Johanna Ivaska's research group at Turku Bioscience observed that SORLA functionally contributes to the most reported therapy-resistant mechanism by which the cell-surface receptor HER3 counteracts HER2 targeting therapy in HER2-positive cancers. Removing SORLA from cancer cells sensitized anti-HER2 resistant breast cancer brain metastasis to targeted therapy. (2021-01-29)

First hybrid gene therapy shows early promise in treating long QT syndrome
In a new study published in Circulation, Mayo Clinic researchers provide the first preclinical, proof-of-concept study for hybrid gene therapy in long QT syndrome, a potentially lethal heart rhythm condition. (2021-01-28)

Gut microbiota reveals whether drug therapies work in inflammatory bowel diseases
A study recently completed at the University of Helsinki indicates that the gut microbiota of patients suffering from inflammatory gastrointestinal disorders can be used to predict whether they will benefit from expensive therapies. The study also confirms the key role of therapies that have a beneficial effect on the gut microbiota in inflammatory bowel diseases. (2021-01-26)

Investigational combo therapy shows benefit for TP53 mutant MDS and AML patients
Moffitt Cancer Center is leading a national, multicenter clinical trial investigating a new therapy option for this group of patients. It builds upon the standard of care therapy, combining eprenetapopt (APR-246) with the chemotherapy azacitidine. Results of the phase 1b/2 trial to determine the safety, recommended dose and efficacy of the combination therapy were published in the Journal of Clinical Oncology. (2021-01-21)

Genome editing to treat human retinal degeneration
Gene editing therapies, including CRISPR-Cas systems, offer the potential to correct mutations causing inherited retinal degenerations, a leading cause of blindness. Technological advances in gene editing, continuing safety concerns, and strategies to overcome these challenges (2021-01-19)

Biodistribution of AAV gene transfer vectors in nonhuman primate
The biodistribution of adeno-associated virus (AAV) gene transfer vectors can be measured in nonhuman primates using a new method. The method quantifies whole-body and organ-specific AAV capsids from 1 to 72 hours after administration (2021-01-15)

T cells linked to myelin implicated in MS-like disease in monkeys
Scientists have uncovered new clues implicating a type of herpes virus as the cause of a central nervous system disease in monkeys that's similar to multiple sclerosis in people. By linking two specific T cells to the loss of myelin, scientists say the new study opens the possibility of developing an antiviral therapy that could be especially useful for newly diagnosed cases of multiple sclerosis. (2021-01-15)

Treatment for chronic pain must address both physical and social pain
Physical pain and social pain may be more closely related than previously thought. Social pain, which typically results from interpersonal rejection or abuse, has been viewed as a non-medical response to external factors. However, recent research suggests that some physical and social stress responses may arise because of shared processing in the brain. (2021-01-12)

Gene therapy strategy found effective in mouse model of hereditary disease TSC
Patients with a genetic disorder called tuberous sclerosis complex have noncancerous tumors growing in numerous organs, and their treatment options are limited. A gene therapy strategy effectively treated mice that express one of the mutated genes that cause the disease. (2021-01-08)

A prognostic Alzheimer's disease blood test in the symptom-free stage
Using a blood test, a German-Dutch research team has predicted the risk of Alzheimer's disease in people who were clinically diagnosed as not having Alzheimer's disease but who perceived themselves as cognitively impaired (Subjective Cognitive Declined, SCD). The researchers analyzed blood samples from an SCD cohort supervised at the Alzheimer Center Amsterdam. Using a test developed in Bochum, they identified all 22 subjects at study entry who developed Alzheimer's dementia, thus the clinical symptoms, within six years. (2021-01-06)

Ibrutinib with rituximab in previously untreated CLL: indication of added benefit over FCR
Ibrutinib with rituximab in previously untreated CLL: indication of added benefit over FCR. The new drug combination prolongs overall survival in patients in good general health. No study data are available for other patient groups. (2021-01-05)

Oral hormone therapy shown to significantly alter metabolome of menopausal women
Groundbreaking research led by a team of scientists including a University of Massachusetts Amherst biostatistician shows that oral hormone therapy (HT) significantly alters the metabolome of postmenopausal women. This finding, which examined blood specimens from the landmark Women's Health Initiative (WHI) study, may help explain the disease risks and protective effects associated with different regimens of hormone therapy. (2020-12-16)

Gene therapy for placental insufficiency moves toward the clinic
A new study identified an adenovirus gene therapy vector carrying a VEGF isoform. It can improve uterine blood flow in placental insufficiency. (2020-12-15)

Robots could replace real therapy dogs
Robotic animals could be the 'pawfect' replacement for our real-life furry friends, a new study published today by the University of Portsmouth has found. (2020-12-10)

Phase 1 trial assesses whether fecal microbiota transplant impacts cancer patients resistant to immu
In one of the first in-human studies to investigate whether modifying the gut microbiome by a fecal microbiota transplant could make cancer immunotherapy more effective, researchers analyzing this in ten cancer patients with refractory melanoma suggest the treatment can improve patient outcomes. (2020-12-10)

AAV capsid-promoter interactions in the non-human primate brain
The phenomenon of AAV capsid-promoter interaction recently seen in the rat central nervous system has now been shown to occur in the non-human primate brain. This interaction can directly determine cell-specific transgene expression (2020-12-10)

High-risk, HR+, HER2-, early-stage BC patients continue to benefit from abemaciclib
Extended follow-up data from the phase III monarchE trial showed that adding the cyclin-dependent kinase (CDK) inhibitor abemaciclib (Verzenio) to standard adjuvant endocrine therapy continued to improve invasive disease-free survival (IDFS) among patients with high-risk, node-positive, early-stage, HR-positive, HER2-negative breast cancer, according to data presented at the 2020 San Antonio Breast Cancer Symposium. (2020-12-09)

Omitting radiation therapy after breast-conserving surgery may not impact 10-year survival rates for older patients with HR-positive breast cancer
Older patients with hormone receptor-positive breast cancer who did not receive radiation therapy after breast-conserving surgery had higher rates of local recurrence but similar 10-year survival rates when compared to patients who received postoperative radiation therapy, according to updated 10-year data from the PRIME II study, presented at the 2020 San Antonio Breast Cancer Symposium. (2020-12-09)

Single-eye gene therapy improves vision in both eyes of patients with inherited eye disorder
A gene therapy for an inherited eye disorder can ameliorate vision loss in both eyes despite only being injected into one, according to a phase 3 clinical trial involving 37 patients. (2020-12-09)

CAR T cell therapy effective as first-line treatment for high-risk large B-cell lymphoma
A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments. (2020-12-06)

Mimicking the effect of exercise with gene therapy
Gene therapy is the most effective method to be able to provide health benefits you normally gain through physical exercise. This means of ''training'' could be helpful for folks who can't exercise in the usual ways. (2020-12-04)

Secukinumab in children with plaque psoriasis: Study unsuitable for benefit assessment
Secukinumab in children with plaque psoriasis: study unsuitable for benefit assessment The comparator group was not treated appropriately. Firstly, therapy in this group remained unchanged despite non-response, and secondly, it was continued for longer than approved. (2020-12-04)

Lung tissue from COVID-19 patients and others reveals promising target to treat lung fibrosis
An analysis of lung tissues from patients with different types of pulmonary fibrosis - including cases triggered by COVID-19 - has revealed a promising molecular target to ameliorate the chronic and irreversible disease. Experiments in mouse models of lung fibrosis showed that administering blockers of (2020-12-04)

Gene therapy gives man with sickle cell disease the chance for a better future
Watch a video about Evie's treatment with an experimental gene therapy for sickle cell disease here: https://www.youtube.com/watch?v=XmQJpuLx07Y (2020-11-30)

Scientists develop new gene therapy for eye disease
Scientists from Trinity College Dublin have developed a new gene therapy approach that offers promise for one day treating an eye disease that leads to a progressive loss of vision and affects thousands of people across the globe. The study, which involved a collaboration with clinical teams in the Royal Victoria Eye and Ear Hospital and the Mater Hospital, also has implications for a much wider suite of neurological disorders associated with ageing. (2020-11-26)

In-stent thrombosis after antiplatelet therapy conversion while awaiting coronary bypass
In a new publication from Cardiovascular Innovations and Applications; DOI https://doi.org/10.15212/CVIA.2019.0589, Nathan Burke, Tawanna Charlton, Hussam Hawamdeh, and Ki Park from the University of Florida College of Medicine, Gainesville, Florida, USA consider a case study of in-stent thrombosis after antiplatelet therapy conversion while awaiting coronary bypass. (2020-11-19)

Home oxygen therapy for adults with COPD and ILD: New ATS clinical practice guideline
The latest clinical practice guideline on home oxygen therapy addresses long-term and ambulatory oxygen therapy for adults with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) and includes the most comprehensive review of the evidence of any oxygen guideline to date. (2020-11-17)

NIH gene therapy startup to increase AAV gene therapy efficiency
Maximizing the efficiency of the adeno-associated virus (AAV) platform for gene therapy is the aim of a new pilot project of the National Institutes of Health (NIH). (2020-11-17)

Reversal of glial scar tissue back to neuronal tissue through neuroregenerative gene therapy
Brain or spinal cord injury often results in glial scar tissue that is correlated to neural functional loss. Glial scar is a well-known obstacle for neural regeneration. A research team led by Prof. Gong Chen at Jinan University, Guangzhou, published an article in the current issue of Frontiers in Cellular Neuroscience, demonstrating that glial scar tissue can be reversed back to neuronal tissue through NeuroD1-based neuroregenerative gene therapy. (2020-11-16)

Risk of AAV mobilization in gene therapy
New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy. These findings, which emphasize the need for mobilization resistant AAV vectors (2020-11-13)

Penn researchers develop approach to prevent toxicity tied to neurological gene therapy
Penn Medicine researchers have developed a new targeted approach to prevent a toxicity seen in the sensory neurons of dorsal root ganglia after gene therapy to treat neurological disorders. It's an important hurdle to clear, as the field works toward more safe and effective gene therapies for patients with disorders like spinal muscular atrophy. (2020-11-11)

Page 1 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.